HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6
Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
1 .- 51 . (canceled)
52 . A construct that binds human CLDN6 comprising:
a) a heavy chain variable domain having an amino acid sequence that is 90% identical to SEQ ID NO:233; and
b) a light chain variable domain having an amino acid sequence that is 90% identical to SEQ ID NO:369.
53 . The construct of claim 52 , wherein the heavy chain variable domain has an amino acid sequence that is 95% identical to SEQ ID NO:233; and the light chain variable domain has an amino acid sequence that is 95% identical to SEQ ID NO:369.
54 . The construct of claim 52 , wherein the heavy chain variable domain has an amino acid sequence that is SEQ ID NO:233; and the light chain variable domain has an amino acid sequence that is SEQ ID NO:369.
55 . A nucleic acid composition encoding the construct of claim 52 comprising:
a) a first nucleic acid encoding the heavy chain variable domain; and
b) a second nucleic acid encoding the light chain variable domain.
56 . An expression vector composition encoding the construct of claim 52 comprising:
a) a first expression vector comprising a first nucleic acid encoding the heavy chain variable domain; and
b) a second expression vector comprising a second nucleic acid encoding the light chain variable domain.
57 . A host cell comprising the expression vector composition of claim 56 .
58 . A method of making a construct comprising culturing the host cell of claim 57 under conditions wherein the construct is expressed and recovering the construct.